Elite Pharma Technology Closes ￥10M Series A Funding Round

According to lieyunwang.com, Elite Pharma Technology (Shanghai) Co., Ltd. ("Elite Pharma") has completed its Series A round of tens of millions yuan, with participation from Kaitai Capital and South China Venture Capital. 

Elite Pharma focuses on the research and development of the new drug delivery technology and platform. At present, the company has pipelines of sustained-release preparations based on the osmotic drug delivery system. It has established a unique platform of osmotic pumps and controlled-release kinetics with tablets. There are more than 10 products in development, covering the treatment of chronic diseases, such as high blood pressure, diabetes, and so on.

Founded in December 2010 in the United States, Elite Pharma is engaged in the development and innovation of pharmaceutical processes and drug delivery technologies to manufacture derivative and original new drugs. The company makes use of its unique osmotic drug delivery technology and controlled-release tablets to develop drugs. 

The core founding team of Elite Pharma has more than 20 years of working experience in pharmaceutical research and development, process development, drug production and drug registration.

Kaitai Capital has always been focused on the clinical unmet needs and participated in many investments of the biopharmaceutical industry. To date, the company has invested in more than 70 companies in the fields of treatments in tumors, metabolic diseases, cardiovascular diseases, anti-infection, autoimmunity, neuroscience, skin diseases, and respiratory diseases.

Kaitai Capital, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc. Currently, the asset under management of Kaitai Capital has reached 50 billion yuan (US$7.2 billion).

Founded in March 2008, SCVC is a private equity investment fund manager, mainly focusing on professional investment, management and organization. The company has issued and managed five private equity funds, with a management scale of more than 2.6 billion.

SCVC is engaged in investments covering real estate, logistics, building materials, electric power, docks, hotels, electronic security, and other areas.